MyFinsight
Home
Blog
About
Cash and cash
equivalents
$8,068,357
(-66.15%↓ Y/Y)
Short-term investments
$1,995,784
(-91.94%↓ Y/Y)
Other current assets
$479,582
(-34.61%↓ Y/Y)
Prepaid expenses
$415,164
(-67.15%↓ Y/Y)
Total current assets
$10,958,887
(-78.33%↓ Y/Y)
Operating lease
right-of-use asset
$33,660
(-90.53%↓ Y/Y)
Property and equipment,
net
$32,939
(-97.18%↓ Y/Y)
Other assets
$8,309
(-84.59%↓ Y/Y)
Total assets
$11,033,795
(-78.85%↓ Y/Y)
Accumulated deficit
-$210,170,441
(-31.62%↓ Y/Y)
Total liabilities and
stockholders equity...
$11,033,795
(-78.85%↓ Y/Y)
Total stockholders
equity (deficit)
-$497,307
(-101.14%↓ Y/Y)
Additional
paid-in-capital
$209,637,990
(3.11%↑ Y/Y)
Common stock, 0.001 par
value 300,000,000 and...
$35,144
(13.41%↑ Y/Y)
Total liabilities
$11,531,102
(35.91%↑ Y/Y)
Total current
liabilities
$11,531,102
(38.73%↑ Y/Y)
Estimate for accrued
legal contingencies...
$5,417,250
(199.95%↑ Y/Y)
Accounts payable
$4,278,419
(32.77%↑ Y/Y)
Other current
liabilities
$966,121
(-56.48%↓ Y/Y)
Accrued payroll
liabilities
$690,566
(-20.44%↓ Y/Y)
Insurance premium loan
payable
$143,050
Operating lease
liability, current portion
$35,696
(-81.70%↓ Y/Y)
Back
Back
Balance Sheet
Skye Bioscience, Inc. (SKYE)
Skye Bioscience, Inc. (SKYE)
source: myfinsight.com